Heterogeneous_JJ
expression_NN
of_IN
Epstein-Barr_JJ
virus_NN
latent_JJ
proteins_NNS
in_IN
endemic_JJ
Burkitt_NN
's_POS
lymphoma_NN
._.

Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
-_:
infected_JJ
cells_NNS
may_MD
sustain_VB
three_CD
distinct_JJ
forms_NNS
of_IN
virus_NN
latency_NN
._.

In_IN
lymphoblastoid_JJ
cell_NN
lines_NNS
,_,
six_CD
EBV-encoded_JJ
nuclear_JJ
antigens_NNS
-LRB-_-LRB-
EBNA1_NN
,_,
2_CD
,_,
3A_NN
,_,
3B_NN
,_,
3C_NN
,_,
-_:
LP_NN
-RRB-_-RRB-
,_,
three_CD
latent_JJ
membrane_NN
proteins_NNS
-LRB-_-LRB-
LMP1_NN
,_,
2A_NN
,_,
2B_NN
-RRB-_-RRB-
,_,
and_CC
two_CD
nuclear_JJ
RNAs_NNS
-LRB-_-LRB-
EBERs_NNS
-RRB-_-RRB-
are_VBP
expressed_VBN
._.

This_DT
form_NN
of_IN
latency_NN
,_,
termed_VBN
latency_NN
III_CD
,_,
is_VBZ
also_RB
encountered_VBN
in_IN
some_DT
posttransplant_JJ
lymphoproliferative_JJ
disorders_NNS
._.

In_IN
EBV-positive_JJ
cases_NNS
of_IN
Hodgkin_NN
's_POS
disease_NN
,_,
the_DT
EBERs_NNS
,_,
EBNA1_NN
,_,
and_CC
the_DT
LMPs_NNS
are_VBP
expressed_VBN
-LRB-_-LRB-
latency_NN
II_CD
-RRB-_-RRB-
,_,
whereas_IN
in_IN
Burkitt_NN
's_POS
lymphoma_NN
-LRB-_-LRB-
BL_NNS
-RRB-_-RRB-
only_RB
the_DT
EBERs_NNS
and_CC
EBNA1_NN
have_VBP
been_VBN
detected_VBN
-LRB-_-LRB-
latency_NN
I_CD
-RRB-_-RRB-
._.

We_PRP
have_VBP
studied_VBN
the_DT
expression_NN
of_IN
EBV_NN
proteins_NNS
in_IN
17_CD
cases_NNS
of_IN
EBV-positive_JJ
endemic_JJ
BL_NNS
by_IN
immunohistology_NN
._.

Expression_NN
of_IN
LMP1_NN
was_VBD
seen_VBN
in_IN
variable_JJ
proportions_NNS
of_IN
tumor_NN
cells_NNS
in_IN
two_CD
cases_NNS
and_CC
EBNA2_NN
was_VBD
detected_VBN
in_IN
some_DT
tumor_NN
cells_NNS
in_IN
three_CD
other_JJ
cases_NNS
._.

Also_RB
,_,
the_DT
BZLF1_NN
trans-activator_NN
protein_NN
was_VBD
expressed_VBN
in_IN
a_DT
few_JJ
tumor_NN
cells_NNS
in_IN
6_CD
cases_NNS
,_,
indicating_VBG
entry_NN
into_IN
the_DT
lytic_JJ
cycle_NN
._.

A_DT
phenotypic_JJ
drift_NN
from_IN
latency_NN
I_NN
to_TO
latency_NN
III_CD
has_VBZ
been_VBN
observed_VBN
previously_RB
in_IN
some_DT
BL_NN
cell_NN
lines_NNS
._.

Our_PRP$
results_NNS
suggest_VBP
that_IN
a_DT
similar_JJ
phenomenon_NN
may_MD
occur_VB
in_IN
BL_NN
in_FW
vivo_FW
and_CC
indicate_VBP
that_IN
the_DT
operational_JJ
definition_NN
of_IN
EBV_NN
latencies_NNS
is_VBZ
not_RB
easily_RB
applied_VBN
to_TO
human_JJ
tumors_NNS
._.

